CD ComputaBio serves as an incubator for many early stage drug development programs towards commercialization. CD ComputaBio offers drug development solutions for worldwide customers based on our artificial intelligence platform. We have successfully accomplished several projects for our target clients across medical institutions, pharmaceutical companies, and government agencies. Our team of scientists is also ready to support your project with comprehensive solutions.
CD ComputaBio, is pleased to offer free resources to make your daily research easier and to help you learn more about our technology and services. Should you be interested in our AI platform and the collaboration opportunity, please contact us at inquiry@protheragen.com.
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry. There are a growing number of applications that address target and drug discovery, preclinical and clinical development, and post-approval activities using AI technologies. The use of AI in life sciences, especially in the field of drug discovery, is set to become widespread within the next decade.
Learn More
Drug development is a costly, time-consuming process, which usually takes an average of 12 years for a new drug to be developed, from the initial R & D stage to finally entering the market. Although the FDA has provided an accelerated approval process, anticancer drugs still take 6-15 years from development to approval. Can artificial intelligence help accelerate this process? The answer is certainly a “YES”. AI will lead to a quicker, cheaper, and more effective drug discovery. The following are four major benefits brought by AI. Let’s have a look.
Learn More